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Pausing for thought: Disrupting the early
transcription elongation checkpoint
leads to developmental defects and
tumourigenesis
Barbara H. Jennings
Factors affecting transcriptional elongation have been
characterized extensively in in vitro, single cell (yeast)
and cell culture systems; however, data from the context
of multicellular organisms has been relatively scarce.
While studies in homogeneous cell populations have
been highly informative about the underlying molecular
mechanisms and prevalence of polymerase pausing,
they do not reveal the biological impact of perturbing
this regulation in an animal. The core components regu-
lating pausing are expressed in all animal cells and are
recruited to the majority of genes, however, disrupting
their function often results in discrete phenotypic effects.
Mutations in genes encoding key regulators of transcrip-
tional pausing have been recovered from several genetic
screens for specific phenotypes or interactions with
specific factors in mice, zebrafish and flies. Analysis of
these mutations has revealed that control of transcrip-
tional pausing is critical for a diverse range of biological
pathways essential for animal development and survival.
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Introduction
Cells within a mature animal differ dramatically in their size,
shape, function, longevity and ability to keep dividing even
though, with few exceptions, every cell contains the same set
of genes. The great diversity of cells found in animals is a
consequence of different cell types expressing different pro-
files of genes during cell fate determination and differen-
tiation. Failure of gene regulation usually has catastrophic
effects on the developing embryo, and in adult life leads to
disease, including cancer.
All gene expression is controlled at the level of RNA
polymerase recruitment and successful formation of the
pre-initiation complex (PIC). Obviously, if RNA polymerase
cannot bind to the transcription start site of a gene, then no
RNA can be transcribed. However, transcription in eukaryotes
may be regulated at several additional levels, including
elongation, processing, termination and export from the
nucleus.
It had been established for over 30 years that transcription
elongation may be a rate-limiting step in gene expression, but
it is only in the past five years or so that the prevalence and
importance of elongation control has been recognized (recent
reviews include [1–4]). Historically, the best-studied example
was regulation of the genes encoding the heat shock proteins
(Hsp) in Drosophila. In the absence of heat shock, transcrip-
tionally engaged RNA polymerase II (RNAP II) accumulates
just downstream of the transcriptional start sites (TSSs) of
Hsp genes and is associated with short 20–60 nucleotide long
nascent RNAs [5, 6]. This phenomenon is often described as
promoter proximal pausing. Upon heat shock, activating
factors trigger the release of RNAP II from promoter proximal
pausing, and there is rapid increase of full-length transcripts
produced from Hsp genes [5, 6].
Another well-studied example of elongation control is
transcription of the HIV provirus [7–9]. Transcription of HIV
is a critical step in the virus’s life cycle. HIV provirus is
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integrated into the host chromatin where it becomes subject to
transcription by host RNAP II to replicate the virus. In the
absence of the Tat activator protein (encoded by HIV), RNAP II
can initiate transcription efficiently and clears the promoter,
but synthesizes short non-polyadenylated transcripts [10].
When Tat is present, it recruits factors that activate transcrip-
tion elongation, including Positive Transcription Elongation
Factor b (P-TEFb; see below) and full-length transcripts of the
virus aremade. Inhibition of transcription elongation has been
one strategy investigated as a therapy for HIV infection.
Other examples of genes showing promoter proximal
pausing emerged into the literature sporadically, including
c-myc and c-fos [11–13]. Then, starting in 2007, the arrival of
new technologies permitting whole genome analysis led to a
slew of studies of RNAP II recruitment and transcript pro-
duction. These studies revealed that promoter proximal paus-
ing is a feature of many metazoan genes [14–16].
RNAP II typically displays an approximately uniform distri-
bution of binding across transcription units in yeast, consistent
with a model in which RNAP II experiences no regulatory
barriers after transcription initiation [17]. However, in higher
eukaryotes RNAP II binding is concentrated near the tran-
scription start site of many genes consistent with promoter
proximal pausing. Guenther et al. [15] demonstrated that
while approximately 75% of protein coding genes in human
embryonic stem cells experience transcription initiation,
only about half of these genes produce detectable full-length
transcripts. Furthermore, two genome-wide screens for pro-
moter proximal paused RNAP II in Drosophila revealed that
approximately 20% of genes in S2 culture cells, and 10% in
early embryos, had initiated transcription but were transcrip-
tionally paused [14, 16]. More recent studies have confirmed
that the majority of RNAP II associated with the promoters of
Drosophila genes is paused and this is a checkpoint that is
widely used to regulate transcription [18, 19].
The current model for RNAP II promoter proximal pausing
and release is largely based on in vitro studies using human
cell lysates (Fig. 1). Briefly, two protein complexes, one con-
taining Spt4 and Spt5 (often referred to as ‘DSIF’) [20] and the
other known as Negative Elongation Factor (NELF) [21], act
together to inhibit transcript elongation beyond 30 nucleo-
tides [2, 22, 23]. For further elongation to occur, the Cdk 9
kinase subunit of P-TEFbmust phosphorylate specific residues
in NELF, Spt5 and RNAP II. This induces the dissociation of
NELF from the polymerase complex, the switch in Spt5 from
being a negative to positive regulator of transcription and
production of the full-length transcript by RNAP II. Spt5 tracks
along with the RNAP II elongation complex until transcription
termination. Recent structural studies have shown that the
‘NGN’ domain of Spt5 sits over the DNA and RNA bound in the
active site of RNA polymerases, where it can directly control
the rate of transcript elongation [24, 25].
Many reviews have recently been written about the
molecular mechanisms controlling promoter proximal paus-
ing [1–4, 22, 23, 26–28], but the biological consequences of
aberrant elongation control have been largely overlooked.
Not surprisingly, null mutations in core factors regulating
the transition into elongation are often lethal to the cells
that carry them, but some are not, and other less severe
aberrations also provide insight into the role of promoter
proximal pausing in animals. The remainder of this essay will
highlight results from animal studies of mutations in core
factors controlling elongation and consider what they reveal
about the role of these factors in biology.
Spt5 function during animal development
Spt5 is involvedwith all transcription; it is conserved across all
three domains of life (eukaryotes, archaea and bacteria) and
interacts with RNA polymerases I, II and III [29]. Given that
Spt5 has such a ubiquitous role in transcription, it is perhaps
surprising then that several mutations in Spt5 have been
recovered from genetic screens for very specific developmental
defects or phenotypic interactions. Thus, Spt5 may provide a
junction between contextual transcriptional regulators and
RNAP II.
The first mutant allele of Spt5 ( foggym806) was recovered
from a genetic screen for mutations affecting neuronal devel-
opment in zebrafish [30]. Homozygous foggym806 fish look
relatively normal but have neuronal defects that ultimately
prove lethal, including a deficit of dopamine-containing
neurons and corresponding excess of serotonin-containing
neurons [31]. foggym806 is a missense mutation that leads to
an amino acid substitution (V1012D) in the very C-terminal
region of Spt5, which is conserved only amongst higher
eukaryotes. Subsequently, null alleles of Spt5 were character-
ized in zebrafish that had originally been generated in a
large-scale screen for mutations affecting embryogenesis
[32, 33]. Fish homozygous for Spt5 null alleles have additional
phenotypes with respect to foggym806 homozygotes, including
Figure 1. Model of promoter proximal pausing and release. Spt4
and Spt5 (DSIF) and NELF act together to inhibit transcript
elongation beyond 20–60 nucleotides. For further elongation to
occur, P-TEFb must phosphorylate specific residues in NELF, Spt5,
and the long C-terminal domain (CTD) of RNAP II. This induces the
dissociation of NELF, the switch in Spt5 from being a repressor
to an activator of transcription, and production of the full-length
transcript by RNAP II.
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reduced pigmentation, short tails, small ears and pericardial
oedema [33].
There is amaternal component to Spt5 expression in zebra-
fish, thus homozygous null animals do contain some residual
wild-type protein. However, the phenotypes observed in these
embryos as the maternal component diminishes are highly
specific and reproducible, indicating that the expression of a
specific subset of genes during development is more sensitive
to a reduction in Spt5 availability than others. Subsequently,
expression profiling of over 10,000 protein coding genes in
zebrafish embryos 24 hours postfertilization identified that
only 5% of genes were differentially expressed between null
mutants and their wild-type siblings [34]. Thus in zebrafish,
a small subset of genes is highly sensitive to Spt5 levels
during embryogenesis, suggesting that they may represent
direct targets of regulation by Spt5. A similar study using
morpholino oligonucleotide-mediated knockdown of Spt5
coupled to time-course microarray analysis of early zebrafish
embryos indicated that Spt5 plays an erythroid-specific role
in early embryogenesis through the induction of gata1 gene
expression [35].
A further zebrafish allele of Spt5 (fh20) was isolated
from a genetic screen to identify genes that control the
posterior migration of facial branchiomotor neurons in the
zebrafish hindbrain [36]. The sequence change in the fh20
allele causes a splicing defect, leading to a mix of correctly
and incorrectly spliced mRNA and a hypomorphic pheno-
type. Spt5 null facial branchiomotor neurons survive to
at least five days postfertilization while failing to migrate
posteriorly in a wild-type host [36]. Thus, Spt5 appears to
play an important role in branchiomotor neuron migration
in zebrafish.
The N-terminal region of Spt5 (NSpt5: lacking the repeats
phosphorylated by P-TEFb) acts in a dominant manner to
disrupt development when expressed in zebrafish embryos
[37]. This variant impairs the repressive function of Spt5 in
vitro and leads to de-repression of hsp70 in the absence of
heat shock in vivo [37].
The Drosophila Spt5W049 allele was recovered from a
genetic screen for maternal factors that affect anterior-
posterior patterning during embryogenesis [38]. When homo-
zygous in the maternal germ line (such that all Spt5 deposited
in the embryo by the mother is the mutant variant), Spt5W049
leads to defects in segmental patterning of the embryo. The
effects of Spt5W049 are gene specific, since expression of
the gap genes is normal while expression of two of the three
primary pair-rule genes, even-skipped (eve) and runt (run), is
aberrant. Furthermore, enhancer-reporter constructs repro-
ducing specific stripes of eve expression are affected differ-
entially by Spt5W049: expression driven by the stripe 2
enhancer is weak but broadened, while expression of stripe
3 appears wild-type. These results indicate that Spt5 is sensi-
tive to the different combinations of trans-acting factors that
drive expression of stripe 2 and stripe 3.
Remarkably, the Spt5W049 missense mutation maps to the
same region of Spt5 as the foggym806 mutation in zebrafish,
implicating this domain of Spt5 in interactions with contextual
factors that regulate its activity during development. Assays
performed in nuclear extracts demonstrated that both the
Foggym806 and W049 protein variants have a diminished abil-
ity to inhibit transcription prior to the phosphorylation events
of the P-TEFb checkpoint [31, 38]. We observed a loss of
repression of eve expression in the early embryo; stripes of
eve pair-rule protein are broadened or fused in late, cellula-
rizing Spt5W049 embryos when the pattern should be fully
resolved into seven distinct stripes. Thus, the inhibitory
activity of Spt5 on transcription prior to the P-TEFb checkpoint
has a role in repression of eve in the early embryo. In wild-type
embryos, a subset of the cells that repress eve expression
during the seven stripe stage re-activate eve expression around
30 minutes later during gastrulation to form interstripes.
Thus, the repressive mechanism involving Spt5 is rapidly
reversible.
Two null alleles of Drosophila Spt5 were recovered in a
genetic screen for factors that modify Presenilin-dependent
Notch phenotypes [39]. These mutations (when heterozygous)
enhance loss-of-function Notch phenotypes, indicating that
Spt5 is required to activate gene expression in response to
Notch signalling. Animals homozygous for the Spt5W049 mis-
sense mutation [38] and null alleles (B.H.J. unpublished data)
show diminished activation of heat shock gene expression in
vivo. Spt5 mediates repression of the eve locus and activation
of heat shock gene expression, thus Spt5 clearly has both
positive and negative effects on transcription in vivo depend-
ent on context.
Very recently, further alleles of Drosophila Spt5 have been
recovered from a genetic screen for factors mediating dosage
compensation [40]. In Drosophila, males (XY) make additional
transcripts from their single X chromosome, to match the
amount transcribed from females (XX). The increased tran-
scription in males is dependent on the MSL complex, which
contains at least five different proteins and two non-coding
RNAs. Rather than localizing to the promoter or TSS, the MSL
complex is found across the gene bodies of active genes [41]
consistent with a model in which it acts during transcription
elongation. Spt5 genetically interacts with genes encoding
components of the MSL complex and Spt5 protein physically
interacts with MSL1. Thus, it seems likely that in the case of
dosage compensation, Spt5’s role is to promote active
elongation across the gene body rather than in establishing
the P-TEFb checkpoint [40].
The NELF complex regulates pausing in
higher eukaryotes
The NELF complex, which is made up of four subunits
(NELF-A, NELF-B, NELF-C/D and NELF-E), is found only in
higher metazoans; it is not found in yeasts or the nematode
Caenorhabditis elegans. NELF is recruited to a large subset of
genes [42] where it physically interacts with DSIF and RNAP II
to establish promoter proximal pausing. Like DSIF, NELF has
been implicated in both activation and repression of tran-
scription; depletion of NELF in Drosophila S2 culture cells
leads to both up and down regulation of target genes [42].
This observation contributed to the model where NELF recruit-
ment influences nucleosome positioning around the TSS and
renders genes in a state where RNAP II can be rapidly recruited
[42, 43].
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Mutations in the human gene encoding the NELF-A subunit
have been implicated in the pathogenesis of Wolf–Hirschhorn
syndrome (WHS). WHS is caused by deletions of the distal part
of the short arm of chromosome 4 that remove theWHSC1 and
WHSC2 genes [44].WHSC2 encodes NELF-A. The clinical pres-
entation of WHS is complex and its severity correlates with the
size of the chromosomal deletion. Clinical features include a
distinctive craniofacial phenotype, growth and mental retar-
dation, seizures and cardiac abnormalities. The precise con-
tribution of WHSC2/NELF-A gene deletions to this syndrome
are not yet understood due to the variability of the associated
chromosomal aberrations that remove numerous genes, and
the lack of good animal models [45].
NELF-B was recovered in a yeast 2-hybrid screen for factors
that interact with breast cancer susceptibility gene BRCA1 and
is sometimes referred to as COBRA1 (co-factor for BRCA1) [46].
NELF-B inhibits the growth of estrogen receptor a (ERa)
positive breast cancer cells in vitro [47] and NELF-B expression
is reduced in several established breast cancer cell lines [48]. A
study of a cohort of breast ductal carcinoma samples from
patients with known clinical outcomes revealed that a low
level of NELF-B mRNA is associated with metastatic breast
cancer [49].
Mice homozygous for a mutation in NELF-B have an inner
cell mass deficiency and die at the time of implantation [50].
Thus, NELF-B plays a critical role in earlymouse embryogenesis.
NELF also plays a critical role during early Drosophila
development [51]. More than half of embryos derived from
maternal germ line clones homozygous for a null allele of
NELF-A cease to develop before the cellular blastoderm stage
and display abnormal nuclear morphology. The remaining
embryos gastrulate normally, however, they generally stop
developing during germband retraction and exhibit head
defects and incomplete dorsal closure. Embryos derived from
maternal germ line clones of a hypomorphic allele of NELF-E
show similar, but less severe developmental defects [51].
Despite the obvious developmental defects, patterning and
expression of endogenous segmentation genes, including eve,
fushi tarazu (ftz), and sloppy paired 1 (slp1) at the cellular
blastoderm stage is apparently normal in both the NELF
maternal germ line clone embryos, although the expression
of some reporter transgenes derived from these genes is
greatly diminished [51].
There is a reduction in activation of immune response
pathways in larvae depleted of NELF by RNAi, supporting a
role for NELF in gene activation [52]. Many genes in the
immune response pathways in Drosophila contain paused
polymerases and are expressed at basal levels in the absence
of pathogens [52]. However, it is interesting to note that
many of the genes encoding effector proteins at the end of
the pathways [e.g. genes encoding antimicrobial peptides
(AMPs) including CecA1, DptB and AttA] do not contain
paused polymerases but do become rapidly and highly
activated. Stimulus-sensing genes, which must always be
expressed at some low level, are more likely to contain paused
polymerases than effector proteins, which need only be
expressed in response to an immune challenge [52]. Thus,
in this example, promoter proximal pausing represents a
mechanism to precisely control levels of gene expression,
rather than to switch gene expression on or off.
NELF localizes to the heat shock genes when they are not
induced, where it collaborates with DSIF to establish pausing.
Depletion of NELF-E in Drosophila salivary glands reduces the
level of paused polymerase found on Hsp70 [53]. For many
years, the presence of paused polymerases was proposed to
contribute to the rapid rate of transcriptional induction upon
heat shock so the observation that depletion of NELF does not
affect the rate of heat shock gene induction perhaps came as
a surprise [54]. Loss of NELF delays the time taken for Hsp
transcription to decrease down to basal levels after the heat
shock stimulus has ceased. The presence of NELF somehow
facilitates the dissociation of heat shock factor from target
genes [54].
The immune and heat shock responses demonstrate that
promoter proximal pausing is not an absolute requirement for
rapid activation of transcription. Moreover, promoter proximal
pausing often appears to suppress expression of inducible
genes to basal levels when there is no stimulus present.
Although it is well established that DSIF and NELF act
together, the biological consequences of perturbing DSIF and
NELF activity are distinct from each other in Drosophila. It is
not possible to make embryos from germ line clones of null
alleles of Spt5 or Spt4 as complete loss of either of these factors
is lethal to cells in Drosophila (B.H.J. unpublished result),
whereas the NELF-A null clones do survive for a time [51].
Disrupting the NELF complex does not alter patterning of
the endogenous eve gene whereas Spt5W049 embryos lose
repression of eve in interstripe regions [38]. Furthermore,
compromising Spt5 activity leads to a diminished induction
of heat shock genes while compromising NELF does not affect
induction, but does affect the rate of recovery back to basal
expression levels.
Direct regulators of P-TEFb activity control
animal development and cancer
pathogenesis
P-TEFb plays a critical role in the activation of all transcription
and the regulation of its activity can be a rate-limiting step in
metazoan gene expression [4, 26–28, 55, 56]. It is made up of
two subunits: Cyclin T and Cdk9. Cdk9 is a protein kinase
whose targets include Spt5, NELF and RNAP II. A number of
factors that interact directly with P-TEFb contribute to regu-
lation of promoter proximal pausing. P-TEFb activity is
regulated directly by its sequestration and release by an inhibi-
tory complex (7SK snRNA/LARP7/HEXIM) and activation by
association with Bromodomain-containing protein 4 (Brd4) or
c-Myc, or by inclusion in ‘super elongation complexes’ (SECs).
7SK snRNP
The 7SK small non-coding RNA (snRNA) inhibits RNAP II
transcription by binding P-TEFb and recruiting an RNA
binding protein HEXIM (HEXIM1 or HEXIM2 in mammals) to
block Cdk9 activity [27]. The La-related protein (LARP7) and
7SK methyl phosphate capping enzyme (MePCE) are constit-
utive components of the 7SK snRNP. Together, they stabilize
the RNA and may be involved in regulation of the release of
B. H. Jennings Prospects & Overviews....
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P-TEFb. The association of P-TEFb with the 7SK snRNP com-
plex is reversible and regulation of this association is a key
mechanism to control P-TEFb activity in cells.
Mice homozygous for a targeted knockout of the HEXIM1
gene (referred to as CLP-1 in some publications) generally die
before birth and have heart defects [57]. Ectopic HEXIM1
expression in the mouse mammary gland decreased estro-
gen-driven ductal morphogenesis and inhibited the expres-
sion of Cyclin D1 [58]. Ligand-bound ERa regulates formation
of the HEXIM1/P-TEFbcomplex in breast cells [58]. The differ-
ent HEXIMs in mammals may interact with different regulat-
ory factors to generate context-specific regulation of P-TEFb
activity [58].
Drosophila contains just one member of the HEXIM family,
which, along with the 7SK snRNA, is ubiquitously expressed
during development [59]. Tissue specific knockdown of
HEXIM in flies (using the GAL4>UAS-RNAi system [60])
indicates that it is required for cell viability. Although
LARP7 is expressed throughout Drosophila development,
there are noticeable differences in levels in different cell types.
For example, LARP7 is expressed strongly in the ommatidial
clusters in the eye imaginal disc and a cluster of cells in
the presumptive notum of the wing disc [59]. Knockdown of
LARP7 in zebrafish by morpholinos leads to severe develop-
mental defects including altered axis formation and possible
neurodegeneration [61].
Brd4
Proteomic analysis of human proteins associated with mouse
Brd4 revealed that Brd4 interacts with P-TEFb [62]. Brd4 has
been implicated in cell cycle control and DNA replication [63].
Brd4 has a positive role in transcription by recruiting active
P-TEFb complexes to acetylated chromatin in promoter
regions [62].
The Drosophila orthologue of Brd4 is encoded by female
sterile (1) homeotic [fs(1)h; sometimes written as fsh]. Fsh is a
Trithorax group protein, whose main action is to maintain
gene expression. Binding of Fsh to promoter regions is pre-
dictive of transcriptional activity in Drosophila S2 cells [64].
Loss of fs(1)h function results in segmental abnormalities
including homeotic transformations in the progeny of mutant
mothers [65].
c-Myc
The c-Myc protein contains a transactivation domain that
interacts directly with the Cyclin T subunit of P-TEFb to stimu-
late transcription by releasing paused polymerases [66–68].
c-Myc regulates expression of many key genes controlling
growth and proliferation during normal animal development,
and plays a major role in cancer pathogenesis [69]. The c-myc
gene is one of the most highly amplified oncogenes isolated
from human cancer [70]. It has been shown in mouse ES cells
that c-Myc stimulates P-TEFb activity to overcome pausing at
many actively expressed genes, including genes driving cell
proliferation [68]. Thus, as a direct target of c-Myc function,
the pausing checkpoint has a critical role in driving cell
proliferation during both animal development and cancer
pathogenesis.
Super elongation complexes (SECs)
A small fraction of P-TEFb is present in SECs where the Cdk9
kinase is highly active [4, 26, 28]. Mutations in a number of
components of SECs have notable phenotypes in animals. In
addition to P-TEFb, a SEC may include AFF1/AF4, AFF4, ELL1,
ELL2, ENL and AF9. The composition of SECs varies and
additional factors are probably involved, creating potential
for regulatory diversity.
Key components of SECs have been identified as frequent
translocation partners of the mixed lineage leukaemia (MLL)
protein in leukaemia [26]. MLL is a DNA binding transcription
factor that is involved with maintaining active transcription
and plays many important roles in development, which
include haematopoietic stem cell development and mainten-
ance. Chromosomal translocations that lead to in frame
fusions of the MLL gene to other proteins are often recovered
from acute and aggressive myeloid and lymphoblastic leukae-
mias. Five integral components of SECs (AFF1/AF4, AFF4,
AF9, ENL and ELL1) are frequent translocation partners to
MLL [71]. Thus the pervading model is the N-terminal DNA
binding domain of MLL fused to a SEC component will
recruit the rest of the SEC and P-TEFb to MLL target genes
to stimulate their expression above normal levels, which can
cause leukaemia [26, 71, 72].
Inactivation of the mouse AFF1/AF4 gene by homologous
recombination led to growth defects and revealed that AFF1/
AF4 is critical for normal lymphocyte development, but not for
other cell types in the haematopoietic system [73]. A missense
mutation in mouse AFF1/AF4 was recovered in a screen for
mutations affecting neuronal cell death and survival [74]. Mice
carrying this mutation show growth retardation and also have
a distinctive jerky ataxic gait, apparent 3–4 weeks after birth
due to impaired motor and balance functioning. Histological
analysis of brain sections revealed that there is a degeneration
of Purkinje cells in the cerebellum from three weeks, leading to
significant atrophy of the cerebellum by six months [75].
The lilliputian (lilli) gene encodes the single AFF-like
protein found in Drosophila, so is the best fly equivalent to
AFF1/AF4. Alleles of lilli were first isolated in a screen for
factors that suppress activated Raf in eye development
(referred to as Su(Raf)2A; [76]). It has been subsequently
recovered from other genetic screens for factors interacting
with Ras signalling [77–80], Dpp/BMP signalling [81] and Wnt
signalling [82] in addition to screens for maternal mutations
affecting segmentation [83, 84]. Thus lilli plays multiple roles
during Drosophila development.
Drosophila contains a single member of the ELL family of
proteins, which is encoded by the Su(Tpl) gene [85]. Mutations
in Su(Tpl) lead to embryonic segmentation defects and genet-
ically interact with the Ras signalling and Notch signalling
pathways [78, 85–87].
Insights into proximal pausing control
from animal studies
Mutations recovered in genes encoding elongation factors have
revealed their involvement in a diverse range of biological
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pathways including the pathogenesis of numerous cancers,
embryonic patterning, haematopoiesis, and also neuronal
development, migration and degeneration. However, we are
only beginning to appreciate the contribution that promoter
proximal pausing and control of P-TEFb activity has during
animal development and adult life.
The core components regulating elongation are expressed
in all cells and recruited to numerous genes; however, dis-
ruption of their function in vivo leads to distinctive defects
revealing that promoter proximal pausing must be influ-
enced by contextual transcription factors. A number of
proteins have been shown to promote P-TEFb recruitment
to stimulate transcription at specific target genes including
heat shock factor, Tat and c-Myc [9, 68]. However, little is
known about which factors interact with DSIF and NELF to
regulate pausing. Loss of NELF does not result in a simple
global effect on transcription [42, 51] so additional factors
must determine which genes are induced or repressed in the
absence of NELF.
Conclusions
Promoter proximal pausing is not an absolute requirement
for either rapid or high induction of gene expression, but
appears to be a common feature at genes that are normally
expressed at some basal level, but which have the capacity to
be rapidly induced by changes in cellular environment.
Expression of such genes requires very precise control as
too little expression may render the cells unable to respond
to incoming signals, and too much may trigger expression
of downstream effectors in the absence of the appropriate
signal.
Rigorous control of cell division is essential in multi-
cellular organisms during development to generate functional
tissues and organs and in adult life to prevent tumours.
Excessive stimulation of P-TEFb activity often leads to
increased cell proliferation; mutations that increase c-Myc
activity or fuse the MLL transcription factor to SEC com-
ponents have been isolated from numerous cancers.
Perhaps the tight control of the P-TEFb checkpoint observed
in higher animals has evolved as an additional barrier to
deregulated cell proliferation.
Animal studies confirm that correct regulation of pro-
moter proximal pausing is critical for development and
health in adult life. Analysis of gene expression changes
in ES cells and other cell culture systems may hint at the
consequences of disrupting the pausing checkpoint in vivo,
but to truly understand the biological relevance and role of
pausing in vivo, more genetic studies in whole model organ-
isms are necessary.
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